E Fund CSI 300 Health Care ETF

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Fosun Pharma Subsidiary Approved for Phase I Clinical Trial of HLX05-N for Metastatic Colorectal Cancer in the US

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Fosun Pharmaceutical's Subsidiary's Venlafaxine Hydrochloride Extended-Release Tablets Approved for Registration

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

Hengrui Pharmaceutical Repurchased 12,056,200 A-shares in April

159892

ARKG

512290

159316

513120

516500

159102

516930

588250

588130

512010

510660

159837

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

prnewswire

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ark Genomic Revolution ETF

Guotai CSI Bio-medicine ETF

iShares Biotechnology ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

VG Health

iShares US Pharma

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

SPDR S&P Biotech

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE STAR Biology and Medicine ETF

Invesco Biotechnology & Genome ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

E Fund CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Bosera Hang Seng Health Care ETF(QDII)

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

01833

589720

516610

159929

CICC has initiated coverage on PA GOODDOCTORwith an Outperform rating and a target price of HKD14.2. The report highlights the company's strategic transformation in healthcare and elderly care, achieving full-year profitability in 2024 and positive operating profit in 2025. CICC expects significant profit growth driven by AI enhancements and operational efficiencies, forecasting EPS of RMB0.2 and RMB0.29 for 2026 and 2027, respectively, with a CAGR of 28.3% from 2025 to 2027.

AASTOCKS News

PA GOODDOCTOR

Guotai SSE STAR Brand Name Drug ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

China Universal 800 Health Care ETF

CICC

CICC Initiates PA GOODDOCTOR  with Outperform Rating, TP HKD14.2

Analyst David Martin PhD of Bloom Burton has reiterated a Buy rating on Microbix Biosystems with a price target of C$0.40. He attributes the recent revenue shortfall to a temporary slowdown in Chinese antigen orders, not structural issues. Demand from non-Chinese customers is increasing, and Microbix has diversified its revenue base, reducing future volatility. This positioning, along with the potential for sales normalization, presents an attractive risk-reward profile.

Tip Ranks

MBX Biosciences

Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand

00241

06618

JD HEALTH and ALI HEALTH shares fell 3%-5% following concerns over new GLP-1 drug sales regulations in Shanghai. CLSA noted that online sales remain unaffected and the impact of potential restrictions would be manageable, as GLP-1 drugs constitute a low percentage of sales. Nomura echoed this sentiment, stating market reactions were overblown and maintaining a Buy rating on JD HEALTH with a target price of HKD67.

- JD HEALTH and ALI HEALTH experienced stock declines due to market concerns over new regulations requiring paper prescriptions for GLP-1 drugs in Shanghai.  
- Despite these concerns, current regulations still permit online sales of diabetes drugs, and both companies reported no operational changes or regulatory instructions.  
- Analysts believe that even if restrictions expand, the financial impact will be manageable, as GLP-1 drug sales represent a low single-digit percentage of overall sales for both firms.

ALI HEALTH

JD HEALTH

Nomura Holdings, Inc.

Nomura

JD HEALTH-R

ALI HEALTH  and JD HEALTH Drop 3%-5% as CLSA Says Impact from GLP-1 Online Sales Restrictions Limited; Nomura: Market Overreacted

02359

159570

Wuxi AppTec plans to raise approximately $1 billion through U.S. dollar-settled zero coupon convertible bonds to enhance its capacity and capabilities. The bonds, convertible to shares at an initial price of HK$153, represent about 9.1% of the enlarged H-share capital. The proceeds will be used for global expansion and corporate purposes. Morgan Stanley, Citigroup, and Goldman Sachs are advising on the issuance.

MorningStar

WUXI APPTEC

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP CSI Pharmaceuticals ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

WuXi AppTec

Morgan Stanley

Citigroup

Goldman Sachs

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds

01801

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.

Unusual Whales

BlackRock, Inc.

iShares Global Healthcare

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

516820

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

159883

159898

The DOJ has initiated a criminal investigation into NYU Langone Health regarding its provision of gender-affirming care for transgender youth. This marks the first known instance of such a probe targeting a hospital for this type of care. NYU Langone received a grand jury subpoena seeking information about minor patients and hospital staff involved in providing this care. The investigation follows a trend of increased scrutiny on transgender rights under the Trump administration, with over 20 subpoenas issued to various hospitals nationwide, leading many to halt gender-affirming treatments for young patients.

Yahoo Finance

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

iShares US Healthcare Providers

iShares US Medical Devices

SPDR S&P Health

SPDR S&P Health Equip

DOJ Launches Criminal Probe Into Blue State Hospital

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Penghua CSI HK Connect Health Care Composite ETF

Microbiotica reports positive results for MB097 in advanced melanoma

E Fund CSI 300 Health Care ETF(512010.SH)